Can you take Aminoglutethimide with Isavuconazonium?

Aminoglutethimide has a major potential interaction with Adrenal Insufficiency.

Aminoglutethimide suppresses adrenal function and is indicated for the treatment of selected cases of Cushing's syndrome. It generally should not be used in patients with adrenocortical insufficiency.

Aminoglutethimide has a moderate potential interaction with Hypotension.

Aminoglutethimide suppresses aldosterone production by the adrenal cortex, which may result in orthostatic or persistent hypotension. Therapy with aminoglutethimide should be administered cautiously in patients with or predisposed to hypotension. Blood pressure should be monitored at regular intervals, and patients should be advised not to rise abruptly from a sitting or recumbent position. Mineralocorticoid replacement therapy may be necessary.

Aminoglutethimide has a moderate potential interaction with Liver Disease.

Aminoglutethimide is primarily metabolized by the liver. Therefore, the clearance and therapeutic activity of the drug may be altered in patients with hepatic impairment. In addition, aminoglutethimide may cause elevated levels of transaminases, alkaline phosphatase, and bilirubin. Therapy with aminoglutethimide should be administered cautiously in patients with compromised hepatic function. Liver function tests should be performed and monitored more closely during therapy.

Isavuconazonium has a moderate potential interaction with Liver Disease.

The use of isavuconazonium has been associated with hepatic adverse reactions (e.g., elevations in ALT, AST, alkaline phosphatase, total bilirubin). Cases of more severe hepatic reactions (including hepatitis, cholestasis, hepatic failure including death) have been reported during therapy in patients with serious underlying medical conditions (e.g., hematologic malignancy). Liver-related laboratory tests should be evaluated at the start and during therapy. Isavuconazonium has not been studied in patients with severe liver dysfunction (Child-Pugh C) and should be used in these patients only when the benefits outweigh the risk. Clinical monitoring for drug-related side effects is recommended when treating patients with severe liver dysfunction.

Aminoglutethimide has a major potential interaction with Panhypopituitarism.

Aminoglutethimide suppresses adrenal function and is indicated for the treatment of selected cases of Cushing's syndrome. It generally should not be used in patients with adrenocortical insufficiency.

Isavuconazonium has a major potential interaction with Short QT Syndrome.

Isavuconazonium shortened the QTc interval in a concentration-related manner. This drug is contraindicated in patients with familial short QT syndrome.